The "Cell & Gene Therapies in Respiratory Disorders: Therapeutic Analysis" report has been added to ResearchAndMarkets.com's offering.

The cell and gene therapies (CGTs) landscape for respiratory diseases is currently in the early stages of development, with no marketed CGTs to date.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the CGT in Respiratory market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact Respiratory disease targeting CGT therapeutics market in the future.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Introduction and Scope

4. Current Treatment Options

4.1. What is Cell & Gene Therapy?

4.2. History of the Development of CGT in Respiratory Disorders

5. Unmet Needs

5.1. Challenges and Opportunities in CGT in Respiratory Disorders

6. Regulations

6.1. Regulation of CGTs in the 8MM

7. Future Market Assessment

7.1. Top 20 Respiratory Disorders with CGT Development

7.2. Top Five Respiratory Disorders with the Most CGT Pipeline Assets

7.3. Top Five Respiratory Disorders Stratified by Molecule Type

7.4. CGT in Respiratory Disorders -Phase II/III

7.5. Industry Trends in the Application of CGTs in Respiratory Disorders

7.6. CGT Market Catalyst are limited to a single company in the next 5 years

8. Likelihood of Approval and Phase - Transition Success Rate Analysis

8.1. CGT Candidates Have Lower PTSR vs. Indication Benchmarks

9. Sales Forecast

9.1. Sales are forecast to reach $62 million by 2030

10. Appendix

Companies Featured

• Vertex Pharmaceuticals Inc
• MediPost Co Ltd
• KYORIN Pharmaceuticals Co Ltd
• Bonus BioGroup Ltd
• Armata Pharmaceuticals Ltd
• Translate Bio Inc
• 4D Molecular Therapeutics Inc
• Suzhou Regend Therapeutics Co Ltd
• MiNK Therapeutics Inc
• Human Life CORD Japan Inc
• Nuwacell Biotechnology Co Ltd
• Taskin Bioregeneration Co

For more information about this report visit https://www.researchandmarkets.com/r/f94g3w

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260101453717/en/